Viking Therapeutics (VKTX) Jefferies 2024 Global Healthcare Conference summary

Program highlights and clinical updates

• Multiple small molecule therapeutics in development for metabolic and endocrine disorders, including obesity, NASH, and rare diseases.

• VK2809, a selective thyroid receptor beta agonist, demonstrated targeted liver delivery and robust efficacy in NASH/MASH patients.

• VK2735, a dual GLP-1/GIP agonist, is advancing in both subcutaneous and oral formulations for obesity.

• VK0214, another thyroid receptor agonist, is in phase 1b for X-linked adrenoleukodystrophy.

NASH/MASH program (VK2809)

• VOYAGE phase 2b study showed significant, dose-dependent liver fat reduction sustained over 52 weeks.

• Up to 75% NASH resolution rate and 57% fibrosis improvement at higher doses after 52 weeks.

• Combined endpoint of NASH resolution and fibrosis improvement reached up to 48% at 10 mg.

• Statistically significant improvements in LDL, triglycerides, ApoB, Lp(a), and ApoC-III.

• Safety profile similar to placebo, with most adverse events mild or moderate.

Obesity program (VK2735)

• Phase 1 and 2 studies showed up to 14.7% weight loss from baseline after 13 weeks of subcutaneous dosing.

• Dose-dependent, progressive weight loss with no plateau observed; GI side effects mostly mild and early in treatment.

• Oral formulation demonstrated up to 5.3% mean weight loss after 28 days, with excellent tolerability and low GI adverse events.

• Ongoing dose escalation in oral study, with plans to move into phase 2 by year-end.

• Type C FDA meeting accepted; next clinical study decision expected this quarter.